World Pharma News Digest - 17.11.2009

0 views
Skip to first unread message

Ruslan David

unread,
Nov 17, 2009, 6:59:47 AM11/17/09
to worldph...@googlegroups.com
Abbott Announces Positive Three-Year Data on Its Fully Bioabsorbable Stent Technology 
Abbott (NYSE: ABT) today announced three-year data from the first 30 patients in the first phase of the ABSORB clinical trial, demonstrating that its fully bioabsorbable drug eluting coronary stent successfully treated coronary artery disease and was absorbed into the walls of treated arteries. 
Read more... 
http://www.worldpharmanews.com/content/view/1024/1/
 
BRILINTA Demonstrated Greater Efficacy Over Clopidogrel in the Most Urgent Clinical Setting 
AstraZeneca announced results of a PLATO sub-analysis in the most serious type of Acute Coronary Syndrome (ACS) patients, those with ST Segment Elevation Myocardial Infarction (STEMI). In this setting, ST segment elevation indicates total obstruction of a coronary artery which warrants emergency surgery with angioplasty, 
Read more... 
http://www.worldpharmanews.com/content/view/1023/1/
 
Sanofi-aventis and Regeneron expand strategic Antibody Collaboration 
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) have entered into agreements to expand and extend their existing global collaboration to discover, develop, and commercialize fully-human therapeutic monoclonal antibodies. 
Read more... 
http://www.worldpharmanews.com/content/view/1022/1/
 
Novartis launches Prevacid® 24 HR over-the-counter 
Novartis announced the availability of Prevacid®24HR (lansoprazole delayed-release capsules 15 mg/acid reducer) over-the-counter in pharmacies and retail stores across the US to treat frequent heartburn. Prevacid®24HR received US Food and Drug Administration (FDA) approval in May 2009. 
Read more... 
http://www.worldpharmanews.com/content/view/1021/1/
 
Nycomed reports continued satisfactory performance in the third quarter 2009 
Nycomed reports continued satisfactory performance in the third quarter 2009, with total net turnover increasing by 0.9% (3.2% in local currencies) to €820.0 million. Pantoprazole sales were resilient after losing patent protection in May in 12 European countries. On a regional basis, sales in most emerging markets exhibited strong growth. The pipeline portfolio advanced significantly. 
Read more... 
http://www.worldpharmanews.com/content/view/1020/1/
 
Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain 
Abbott (NYSE: ABT) announced a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. PG110 is a novel biologic in Phase I clinical trial development that targets NGF for the treatment of chronic pain. 
Read more... 
http://www.worldpharmanews.com/content/view/1019/1/
 
FDA approves GSK's pandemic H1N1 vaccine 
GlaxoSmithKline (GSK) announced that the US Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) for its unadjuvanted influenza A (H1N1) pandemic vaccine. 
Read more... 
http://www.worldpharmanews.com/content/view/1018/1/
 
FDA Commissioner Addresses Nation's Healthcare Professionals on H1N1 Vaccine 
Dr. Margaret Hamburg, Commissioner of Food and Drugs, sent a letter to America's healthcare professionals thanking them for their efforts during the 2009 H1N1 influenza outbreak and providing information on the safety of the 2009 H1N1 vaccines. 
Read more... 
http://www.worldpharmanews.com/content/view/1017/1/
 
PharmaNews.eu / Latest News
 
 
 
 
GSK signs agreement with the WHO to donate 50 million doses of pandemic H1N1 vaccine
http://www.pharmanews.eu/gsk/379-gsk-signs-agreement-with-the-who-to-donate-50-million-doses-of-pandemic-h1n1-vaccine
 
 
 
 
Abbott's XIENCE PRIME™ and XIENCE V® Receive Indications in Europe for Treatment of Patients with Diabetes
http://www.pharmanews.eu/abbott/375-abbotts-xience-prime-and-xience-vr-receive-indications-in-europe-for-treatment-of-patients-with-diabetes
 
 
 
With best regards,
Ruslan David, MD
Administrator/Editor
 
 
PS:
Subscribe to World Pharma News alerts by Email (a free service delivered by Google) -
http://feedburner.google.com/fb/a/mailverify?uri=worldpharmanews&loc=en_US
 
Subscribe to PharmaNews.eu alerts by Email (a free service delivered by Google) -
http://feedburner.google.com/fb/a/mailverify?uri=pharmanewseu&loc=en_US
Reply all
Reply to author
Forward
0 new messages